SCHEMBL7083262

SCHEMBL7083262

COCNC(=O)c1cc(C)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
PKM P14618 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MMP13 P45452 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPK10 P53779 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PYGL P06737 1/20 0.42
PYGM P11217 1/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
XBP1 P17861 1/20 0.42
HTT P42858 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171084 0.86 HPGD (0.50) CTSASMN1; SMN2NPC1RAB9AMEN1
SCHEMBL24405150 0.83 EGLN1 (0.49) CTSASMN1; SMN2MEN1KMT2AMMP13
SCHEMBL3945417 0.83 ALDH1A1 (0.51) SMN1; SMN2RAB9AMEN1KMT2AALDH1A1
SCHEMBL4079623 0.83 KDM4C (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3735813 0.83 GRM5 (0.49) RAB9AKMT2AMMP13ALDH1A1MAPK10
SCHEMBL10274536 0.82 KMT2A (0.50) CTSASMN1; SMN2NPC1RAB9APKM
SCHEMBL107759 0.82 CTSA (0.50) CTSASMN1; SMN2NPC1RAB9APKM
SCHEMBL13852609 0.81 KMT2A (0.52) CTSASMN1; SMN2MEN1KMT2AMMP13
SCHEMBL171037 0.79 EGLN1 (0.55) CTSAMEN1KMT2AMMP13POLB
SCHEMBL168844 0.78 MAOB (0.51) CTSAMEN1KMT2AMMP13KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 CTSA 1591/4885SMN1; SMN2 4337/4885NPC1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.